Morgan Stanley
KYMR icon

Morgan Stanley’s Kymera Therapeutics KYMR Stock Holding History

Morgan Stanley’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.3M Sell
194,843
-17,859
-8% -$1.53M ﹤0.01% 2998
2026
Q1 		$17.7M Sell
212,702
-61,316
-22% -$4.86M ﹤0.01% 3067
2025
Q4 		$21.3M Sell
274,018
-103,781
-27% -$7.01M ﹤0.01% 2879
2025
Q3 		$21.4M Buy
377,799
+140,194
+59% +$6.32M ﹤0.01% 2824
2025
Q2 		$10.4M Buy
237,605
+65,523
+38% +$2.26M ﹤0.01% 3414
2025
Q1 		$4.71M Sell
172,082
-67,681
-28% -$2.47M ﹤0.01% 3974
2024
Q4 		$9.65M Sell
239,763
-248,314
-51% -$11.2M ﹤0.01% 3446
2024
Q3 		$23.1M Sell
488,077
-143,661
-23% -$6.34M ﹤0.01% 2661
2024
Q2 		$18.9M Buy
631,738
+84,598
+15% +$2.93M ﹤0.01% 2730
2024
Q1 		$22M Buy
547,140
+105,862
+24% +$3.79M ﹤0.01% 2592
2023
Q4 		$11.2M Buy
441,278
+101,950
+30% +$1.82M ﹤0.01% 3229
2023
Q3 		$4.72M Sell
339,328
-66,577
-16% -$1.34M ﹤0.01% 3793
2023
Q2 		$9.33M Buy
405,905
+79,583
+24% +$2.28M ﹤0.01% 3233
2023
Q1 		$9.67M Buy
326,322
+88,520
+37% +$2.85M ﹤0.01% 3179
2022
Q4 		$5.94M Buy
237,802
+65,052
+38% +$1.73M ﹤0.01% 3597
2022
Q3 		$3.76M Sell
172,750
-161,399
-48% -$4.25M ﹤0.01% 3928
2022
Q2 		$6.58M Buy
334,149
+148,666
+80% +$3.47M ﹤0.01% 3503
2022
Q1 		$7.85M Buy
185,483
+103,358
+126% +$4.37M ﹤0.01% 3192
2021
Q4 		$5.21M Sell
82,125
-5,436
-6% -$317K ﹤0.01% 3674
2021
Q3 		$5.14M Buy
87,561
+23,873
+37% +$1.38M ﹤0.01% 3658
2021
Q2 		$3.09M Sell
63,688
-287,052
-82% -$12.5M ﹤0.01% 4261
2021
Q1 		$13.6M Buy
350,740
+333,257
+1,906% +$20.1M ﹤0.01% 2328
2020
Q4 		$1.08M Buy
17,483
+12,856
+278% +$627K ﹤0.01% 4617
2020
Q3 		$149K Buy
+4,627
New +$141K ﹤0.01% 5247

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Morgan Stanley's KYMR Position: Q2 2026 in Review

Morgan Stanley reduced its Kymera Therapeutics (KYMR) stake by 8.4% in Q2 2026, selling an estimated $1.53M and leaving 194,843 shares worth $22.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2998.

Morgan Stanley first reported a position in KYMR in Q3 2020 and has held it in 24 quarters since. The position peaked at $23.1M in Q3 2024. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Morgan Stanley held 194,843 shares of Kymera Therapeutics worth $22.3M as of Q2 2026.
  • Morgan Stanley sold 17,859 Kymera Therapeutics shares in Q2 2026, an estimated $1.53M.
  • Kymera Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2998 holding.
  • Morgan Stanley first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Morgan Stanley's Kymera Therapeutics position peaked at $23.1M in Q3 2024.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.